Show simple item record

dc.contributor.authorOrganisation mondiale de la Santé
dc.coverage.spatialGenèveen_US
dc.date.accessioned2017-11-27T09:33:54Z
dc.date.available2017-11-27T09:33:54Z
dc.date.issued2017
dc.identifier.govdocWHO/HIV/2017.34
dc.identifier.urihttps://apps.who.int/iris/handle/10665/259507
dc.description66 p.en_US
dc.language.isofren_US
dc.publisherOrganisation mondiale de la Santéen_US
dc.rightsCC BY-NC-SA 3.0 IGOen_US
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/3.0/igoen_US
dc.subject.meshHIVen_US
dc.subject.meshHIV Infectionsen_US
dc.subject.meshAnti-Retroviral Agentsen_US
dc.subject.meshAnti-HIV Agentsen_US
dc.subject.meshChilden_US
dc.subject.meshAdolescenten_US
dc.subject.meshWomenen_US
dc.subject.meshVulnerable Populationsen_US
dc.titlePrincipales considérations concernant la délivrance différenciée de traitements antirétroviraux à des populations particulières : enfants, adolescents, femmes enceintes ou allaitantes et populations clésen_US
dc.typeTechnical documentsen_US
who.relation.languageVersion10665/258506en_US
dc.rights.holderWorld Health Organizationen_US


Files in this item

Thumbnail

This item appears in the following Collection(‎s)‎

Show simple item record